Galderma Investigational Therapy Nemolizumab Granted FDA Breakthrough Therapy Designation for the Treatment of Patients Suffering from Prurigo Nodularis Press release
Galderma Demonstrates Robust Aesthetic Innovation Pipeline with Initiation of Seven New Clinical Studies Press release
Face Up To Rosacea: Galderma launches new campaign to empower and equip rosacea patients to discuss the true burden of their disease with a dermatologist Press release
Galderma Advances Phase 3 Clinical Study with Nemolizumab in Moderate-to-Severe Atopic Dermatitis Press release
Galderma Announces Positive Phase 2 Results for its Proprietary Liquid Formulation of an Investigational Botulinum Toxin and Approval of New State-of-the-Art Manufacturing Facility Press release
Galderma Receives FDA Approval for AKLIEF® (trifarotene) Cream, 0.005%, the First New Retinoid Molecule for the Treatment of Acne in Over 20 Years Press release
Galderma to become the world’s largest independent global dermatology company after completion of CHF 10.2 billion carve-out of Nestlé Skin Health Press release
Nestlé enters into exclusive negotiations to sell Nestlé Skin Health to a consortium led by EQT and ADIA Press release
Galderma´s Azzalure and Dysport® celebrate a decade of treatment of the glabellar lines Press release
